3 lakh doses of intranasal Covid vaccine sent to hospitals: Bharat Biotech's Krishna Ella

Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the companys executive chairman Krishna Ella said on Sunday.He was speaking on the sidelines of an event here at which a bilateral agreement was signed between the University of Wisconsin UW-Madison Global Health Institute GHI and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru.iNCOVACC, the worlds first intranasal COVID-19 vaccine, was launched on January 26.


PTI | New Delhi | Updated: 05-02-2023 16:47 IST | Created: 05-02-2023 16:37 IST
3 lakh doses of intranasal Covid vaccine sent to hospitals: Bharat Biotech's Krishna Ella
Representative Image Image Credit: ANI
  • Country:
  • India

Bharat Biotech dispatched three lakh doses of its intranasal COVID-19 vaccine to some hospitals two days ago, the company's executive chairman Krishna Ella said on Sunday.

He was speaking on the sidelines of an event here at which a bilateral agreement was signed between the University of Wisconsin (UW)-Madison Global Health Institute (GHI) and the Ella Foundation for the establishment of the first-ever UW-Madison One Health Centre in Bengaluru.

iNCOVACC, the world's first intranasal COVID-19 vaccine, was launched on January 26. The vaccine is now available on CoWIN and priced at Rs 800 for private markets and Rs 325 for the government of India and state governments.

''We dispatched three lakh doses of the world's first intranasal COVID-19 vaccine to some hospitals two days ago,'' Ella said.

On whether Bharat Biotech is looking at exporting the vaccine, he said some countries and international agencies are approaching the company for the intra-nasal vaccine.

iNCOVACC is also the world's first intranasal COVID-19 vaccine to receive approval for the primary 2-dose schedule, and as a heterologous booster dose for adults.

Ella said the UW-Madison One Health Centre in Bengaluru is expected to be operational by the end of 2023.

It will advance the development and production of new vaccines for India. Furthermore, the partnership will enable collaboration across disciplines and geographic boundaries, provide Indian students and researchers access to UW expertise and training, and build research capacity in India, he said.

''Both Ella Foundation and UW-Madison GHI share a common vision to advance innovation in science, research, and knowledge sharing. Establishing the UW-Madison Global One Health Centre holds great significance as it will advance global health through research, education, and community engagement by facilitating student, faculty exchanges, research and education,'' he added.

UW-Madison GHI director Jorge Osorio said, ''We are energised by the opportunity to partner with the Ella Foundation to bring UW knowledge and expertise to expand innovative and impactful health initiatives outside Wisconsin to India.'' The India One Health Centre joins a global network that includes Africa and Latin America and will open new opportunities for research, education, and provide actionable outcomes to benefit humans, animals, and ecosystems that advance equitable and sustainable health across India and the world.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

Give Feedback